{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:42:46Z","timestamp":1792896166641,"version":"4.5.0"},"reference-count":107,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","cancertreatmentreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.ctrv.2016.02.002","type":"journal-article","created":{"date-parts":[[2016,2,14]],"date-time":"2016-02-14T15:38:50Z","timestamp":1455464330000},"page":"61-73","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"special_numbering":"C","title":["Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer"],"prefix":"10.1016","volume":"44","author":[{"given":"Francesca","family":"Vignani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Bertaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Consuelo","family":"Buttigliero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Tucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio V.","family":"Scagliotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Di Maio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2016.02.002_b0005","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctrv.2016.02.002_b0010","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s00520-008-0418-0","article-title":"Impact of skeletal complications on patients\u2019 quality of life, mobility, and functional independence","volume":"16","author":"Costa","year":"2008","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ctrv.2016.02.002_b0015","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: clinical features, pathophysiology and treatment strategies","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2016.02.002_b0020","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00520-014-2437-3","article-title":"Burden of skeletal-related events in prostate cancer: unmet need in pain improvement","volume":"23","author":"Broder","year":"2015","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ctrv.2016.02.002_b0025","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/annonc\/mdi122","article-title":"The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer","volume":"16","author":"Weinfurt","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2016.02.002_b0030","unstructured":"Clinical Trials Endpoints for the Approval of Cancer Drugs and Biologics, US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER) 2007."},{"key":"10.1016\/j.ctrv.2016.02.002_b0035","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/cncr.22991","article-title":"Pathologic fractures correlate with reduced survival in patients with malignant bone disease","volume":"110","author":"Saad","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2016.02.002_b0040","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s00520-006-0203-x","article-title":"Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer","volume":"15","author":"DePuy","year":"2007","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ctrv.2016.02.002_b0045","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.radonc.2004.12.001","article-title":"Pre- and post-treatment daily life function in patients with hormone resistant prostate carcinoma treated with radiotherapy for spinal cord compression","volume":"74","author":"Aass","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctrv.2016.02.002_b0050","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0022-5347(05)00241-7","article-title":"Evaluation of functional outcome and local control after radiotherapy for metastatic spinal cord compression in patients with prostate cancer","volume":"175","author":"Rades","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.ctrv.2016.02.002_b0055","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/j.juro.2007.05.135","article-title":"Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications","volume":"178","author":"Krupski","year":"2007","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.ctrv.2016.02.002_b0060","doi-asserted-by":"crossref","first-page":"883","DOI":"10.3390\/jcm3030883","article-title":"Health resource utilization associated with skeletal-related events in patients with advanced prostate cancer: a European subgroup analysis from an observational, multinational study","volume":"3","author":"Bahl","year":"2014","journal-title":"J Clin Med"},{"key":"10.1016\/j.ctrv.2016.02.002_b0065","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/pcan.2012.42","article-title":"Healthcare utilization and costs associated with skeletal-related events in prostate cancer patients with bone metastases","volume":"16","author":"Hagiwara","year":"2013","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.ctrv.2016.02.002_b0070","first-page":"317","article-title":"The cost of treating skeletal-related events in patients with prostate cancer","volume":"14","author":"Lage","year":"2008","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.ctrv.2016.02.002_b0075","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3111\/13696998.2013.779921","article-title":"Cost of skeletal-related events in European patients with solid tumours and bone metastases: data from a prospective multinational observational study","volume":"16","author":"Hechmati","year":"2013","journal-title":"J Med Econ"},{"key":"10.1016\/j.ctrv.2016.02.002_b0080","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2217\/fon.14.145","article-title":"Metastatic castration-resistant prostate cancer: time for innovation","volume":"11","author":"Tucci","year":"2015","journal-title":"Future Oncol"},{"issue":"Suppl. 2","key":"10.1016\/j.ctrv.2016.02.002_b0085","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1053\/j.seminoncol.2010.10.007","article-title":"Examining the metastatic niche: targeting the microenvironment","volume":"37","author":"Guise","year":"2010","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ctrv.2016.02.002_b0090","series-title":"The physiology and clinical significance of bone histomorphometry: techniques and interpretations","first-page":"143","author":"Parfitt","year":"1983"},{"key":"10.1016\/j.ctrv.2016.02.002_b0095","first-page":"134","article-title":"Targeting bone physiology for the treatment of metastatic prostate cancer","volume":"11","author":"Autio","year":"2013","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.ctrv.2016.02.002_b0100","first-page":"98","article-title":"The distribution of secondary growths in cancer of the breast","volume":"8","author":"Paget","year":"1989","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.ctrv.2016.02.002_b0105","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/aja.2011.164","article-title":"The prostate cancer bone marrow niche: more than just \u2018fertile soil\u2019","volume":"14","author":"Pedersen","year":"2012","journal-title":"Asian J Androl"},{"key":"10.1016\/j.ctrv.2016.02.002_b0110","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nrc3055","article-title":"Cancer to bone: a fatal attraction","volume":"11","author":"Weilbaecher","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctrv.2016.02.002_b0115","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1615\/CritRevEukarGeneExpr.v22.i2.50","article-title":"Prostate cancer and parasitism of the bone hematopoietic stem cell niche","volume":"22","author":"Yu","year":"2012","journal-title":"Crit Rev Eukaryot Gene Expr"},{"key":"10.1016\/j.ctrv.2016.02.002_b0120","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s10555-013-9476-y","article-title":"A multi-targeted approach to treating bone metastases","volume":"33","author":"Camacho","year":"2014","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.ctrv.2016.02.002_b0125","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/jcb.10522","article-title":"Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo","volume":"89","author":"Sun","year":"2003","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.ctrv.2016.02.002_b0130","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/pros.20500","article-title":"Expression and activation of \u03b1v\u03b23 integrins by SDF-1\/CXC12 increases the aggressiveness of prostate cancer cells","volume":"67","author":"Sun","year":"2007","journal-title":"Prostate"},{"key":"10.1016\/j.ctrv.2016.02.002_b0135","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.beem.2008.01.011","article-title":"Mechanisms of bone metastasis in prostate cancer: clinical implications","volume":"22","author":"Msaouel","year":"2008","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2016.02.002_b0140","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/pcan.2008.10","article-title":"Prognostic significance of disordered calcium metabolism in hormone-refractory prostate cancer patients with metastatic bone disease","volume":"12","author":"Tucci","year":"2009","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.ctrv.2016.02.002_b0145","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1159\/000463996","article-title":"Hyperparathyroidism in metastases of prostate carcinoma. A biochemical, hormonal and histomorphometric study","volume":"17","author":"Rico","year":"1990","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctrv.2016.02.002_b0150","first-page":"31","article-title":"Pamidronate in the treatment of bone metastases: results of 2 dose-ranging trials in patients with breast or prostate cancer","volume":"5","author":"Lipton","year":"1994","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2016.02.002_b0155","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2016.02.002_b0160","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2016.02.002_b0165","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdu519","article-title":"Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events","volume":"26","author":"Smith","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2016.02.002_b0170","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S1470-2045(14)70303-1","article-title":"Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial","volume":"15","author":"Fizazi","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2016.02.002_b0175","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/S1470-2045(12)70473-4","volume":"13","author":"Logothetis","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2016.02.002_b0180","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(14)70183-4","article-title":"Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial","volume":"15","author":"Sartor","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2016.02.002_b0185","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1200\/JCO.1996.14.6.1756","article-title":"Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points","volume":"14","author":"Tannock","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2016.02.002_b0190","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1200\/JCO.1999.17.8.2506","article-title":"Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study","volume":"17","author":"Kantoff","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2016.02.002_b0195","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2016.02.002_b0200","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2016.02.002_b0205","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.2007.12.4008","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study","volume":"26","author":"Berthold","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2016.02.002_b0210","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1200\/JCO.2007.11.4769","article-title":"Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer","volume":"25","author":"Armstrong","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2016.02.002_b0215","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1158\/1078-0432.CCR-07-0944","article-title":"Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study","volume":"14","author":"Berthold","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2016.02.002_b0220","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"STAMPEDE investigators. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","author":"James","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2016.02.002_b0225","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1158\/1078-0432.CCR-08-0596","article-title":"Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors","volume":"15","author":"Mita","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2016.02.002_b0230","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1358\/dot.2010.46.10.1519019","article-title":"Cabazitaxel, a new taxane with favorable properties","volume":"46","author":"Bouchet","year":"2010","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.ctrv.2016.02.002_b0235","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"De Bono","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2016.02.002_b0240","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1093\/annonc\/mdt194","article-title":"Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial","volume":"24","author":"Bahl","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2016.02.002_b0245","doi-asserted-by":"crossref","DOI":"10.1111\/bju.13069","article-title":"Final quality of life and safety data for patients with metastatic castration-resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme (EAP) (NCT01254279)","author":"Bahl","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.ctrv.2016.02.002_b0250","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrd3516","article-title":"Abiraterone acetate","volume":"10","author":"Logothetis","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ctrv.2016.02.002_b0255","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2016.02.002_b0260","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","article-title":"Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study","volume":"13","author":"Fizazi","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2016.02.002_b0265","doi-asserted-by":"crossref","first-page":"12520","DOI":"10.18632\/oncotarget.3724","article-title":"Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment","volume":"6","author":"Iuliani","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2016.02.002_b0270","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2016.02.002_b0275","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.eururo.2015.04.032","article-title":"Impact of bone-targeted therapies in chemotherapy-na\u00efve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302","volume":"68","author":"Saad","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctrv.2016.02.002_b0280","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/bju.12857","article-title":"Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: results of the Italian named patient programme","volume":"115","author":"Caffo","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.ctrv.2016.02.002_b0285","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1126\/science.1168175","article-title":"Development of a second-generation antiandrogen for treatment of advanced prostate cancer","volume":"324","author":"Tran","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.ctrv.2016.02.002_b0290","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2016.02.002_b0295","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2016.02.002_b0300","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S1470-2045(15)70113-0","volume":"16","author":"Loriot","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2016.02.002_b0305","doi-asserted-by":"crossref","first-page":"6250","DOI":"10.1158\/1078-0432.CCR-06-0841","article-title":"High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?","volume":"12","author":"Bruland","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2016.02.002_b0310","first-page":"252","article-title":"Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice","volume":"44","author":"Henriksen","year":"2003","journal-title":"J Nucl Med"},{"issue":"Suppl. 1","key":"10.1016\/j.ctrv.2016.02.002_b0315","first-page":"38S","article-title":"Bone-seeking radionuclides for therapy","volume":"46","author":"Lewington","year":"2005","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ctrv.2016.02.002_b0320","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"issue":"Suppl. 6","key":"10.1016\/j.ctrv.2016.02.002_b0325","article-title":"Pain analysis from the phase III randomized ALSYMPCA study with radium-223 (Ra-223) in patients with castration-resistant prostate cancer (CRPC) with bone metastases","volume":"31","author":"Nilsson","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2016.02.002_b0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2015.09.005","article-title":"Radiopharmaceuticals for palliation of bone pain in patients with castration-resistant prostate cancer metastatic to bone: a systematic review","author":"Jong","year":"2015","journal-title":"Eur Urol"},{"issue":"10","key":"10.1016\/j.ctrv.2016.02.002_b0335","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/jnci\/djk178","article-title":"Medical Research Council PR04 collaborators. Oral sodium clodronate for nonmetastatic prostate cancer-results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873)","volume":"99","author":"Mason","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"17","key":"10.1016\/j.ctrv.2016.02.002_b0340","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1093\/jnci\/djg038","article-title":"Medical Research Council Pr05 collaborators. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial)","volume":"95","author":"Dearnaley","year":"2003","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"10.1016\/j.ctrv.2016.02.002_b0345","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S1470-2045(09)70201-3","article-title":"Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials","volume":"10","author":"Dearnaley","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2016.02.002_b0350","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2016.02.002_b0355","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/cncr.23529","article-title":"Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid","volume":"113","author":"Lipton","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2016.02.002_b0360","doi-asserted-by":"crossref","unstructured":"James ND, Pirrie S, Barton D, Brown JE, Billingham L, Collins SI et al. Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial TRAPEZE trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both Abstract Number: LBA5000, presented at ASCO 2013 Annual Meeting.","DOI":"10.1200\/jco.2013.31.18_suppl.lba5000"},{"key":"10.1016\/j.ctrv.2016.02.002_b0365","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1200\/JCO.2013.51.6500","article-title":"Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance)","volume":"32","author":"Smith","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2016.02.002_b0370","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.eururo.2014.02.014","article-title":"Prevention of bone metastases in patients with high-risk non metastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS)","volume":"67","author":"Wirth","year":"2015","journal-title":"Eur Urol"},{"issue":"10","key":"10.1016\/j.ctrv.2016.02.002_b0375","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/S1470-2045(14)70328-6","volume":"15","author":"Denham","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2016.02.002_b0380","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdu519","article-title":"Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events","volume":"26","author":"Smith","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2016.02.002_b0385","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","article-title":"Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial","volume":"379","author":"Smith","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2016.02.002_b0390","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1200\/JCO.2012.44.6716","article-title":"Denosumab and bone metastasis-free survival in men with non metastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time","volume":"31","author":"Smith","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2016.02.002_b0395","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","volume":"10","author":"Yakes","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2016.02.002_b0400","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/S0090-4295(02)01954-4","article-title":"High expression of the Met receptor in prostate cancer metastasis to bone","volume":"60","author":"Knudsen","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.ctrv.2016.02.002_b0405","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1200\/JCO.2012.45.0494","article-title":"Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial","volume":"3","author":"Smith","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2016.02.002_b0410","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.eururo.2014.02.013","article-title":"Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort","volume":"67","author":"Basch","year":"2015","journal-title":"Eur Urol"},{"issue":"Suppl. 7","key":"10.1016\/j.ctrv.2016.02.002_b0415","article-title":"Final analysis of COMET-1: cabozantinib versus prednisone in metastatic castration-resistant prostate cancer (mCRPC) patients previously treated with docetaxel and abiraterone and\/or enzalutamide","volume":"33","author":"Smith","year":"2015","journal-title":"J Clin Oncol"},{"issue":"Suppl. 7","key":"10.1016\/j.ctrv.2016.02.002_b0420","article-title":"Final analysis of COMET-2: cabozantinib versus mitoxantrone\/prednisone in metastatic castration-resistant prostate cancer (mCRPC) patients with moderate to severe pain who were previously treated with docetaxel and abiraterone and\/or enzalutamide","volume":"33","author":"Basch","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2016.02.002_b0425","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.coph.2008.06.012","article-title":"Src and focal adhesion kinase as therapeutic targets in cancer","volume":"8","author":"Brunton","year":"2008","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.ctrv.2016.02.002_b0430","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1464-410X.2008.08249.x","article-title":"Src as a therapeutic target in men with prostate cancer and bone metastases","volume":"103","author":"Saad","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.ctrv.2016.02.002_b0435","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ctrv.2009.11.005","article-title":"SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer","volume":"36","author":"Saad","year":"2010","journal-title":"Cancer Treatment Rev"},{"key":"10.1016\/j.ctrv.2016.02.002_b0440","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/cncr.26204","article-title":"Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1\u20132 study","volume":"118","author":"Araujo","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2016.02.002_b0445","doi-asserted-by":"crossref","first-page":"7421","DOI":"10.1158\/1078-0432.CCR-09-1691","article-title":"Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer","volume":"15","author":"Yu","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2016.02.002_b0450","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S1470-2045(13)70479-0","article-title":"Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial","volume":"14","author":"Araujo","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2016.02.002_b0455","doi-asserted-by":"crossref","first-page":"6964","DOI":"10.1073\/pnas.85.18.6964","article-title":"Primary structure, synthesis, and biological activity of rat endothelin, an endothelium-derived vasoconstrictor peptide","volume":"85","author":"Yanagisawa","year":"1988","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ctrv.2016.02.002_b0460","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1038\/nm0995-944","article-title":"Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate","volume":"1","author":"Nelson","year":"1995","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2016.02.002_b0465","first-page":"663","article-title":"Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer","volume":"56","author":"Nelson","year":"1996","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2016.02.002_b0470","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1097\/01.ju.0000042162.08938.27","article-title":"Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan","volume":"169","author":"Nelson","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.ctrv.2016.02.002_b0475","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1097\/01.ju.0000096372.07687.86","article-title":"Endothelin inhibition: novel therapy for prostate cancer","volume":"170","author":"Nelson","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.ctrv.2016.02.002_b0480","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00345-004-0478-9","article-title":"Endothelin receptor antagonists","volume":"23","author":"Nelson","year":"2005","journal-title":"World J Urol"},{"key":"10.1016\/j.ctrv.2016.02.002_b0485","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1002\/cncr.23864","article-title":"Phase 3, randomized, controlled trial of atrasentan in patients with non metastatic, hormone-refractory prostate cancer","volume":"113","author":"Nelson","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2016.02.002_b0490","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1200\/JCO.2012.46.4149","article-title":"Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer","volume":"31","author":"Fizazi","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2016.02.002_b0495","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/pcan.2013.2","article-title":"Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer","volume":"16","author":"Miller","year":"2013","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.ctrv.2016.02.002_b0500","doi-asserted-by":"crossref","first-page":"5709","DOI":"10.1002\/cncr.27674","article-title":"Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone","volume":"118","author":"Nelson","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2016.02.002_b0505","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2174\/138161207780162962","article-title":"Emerging roles of cysteine cathepsins in disease and their potential as drug targets","volume":"13","author":"Vasiljeva","year":"2007","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.ctrv.2016.02.002_b0510","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.1021\/cr0101656","article-title":"Human and parasitic papain-like cysteine proteases: their role in physiology and pathology and recent developments in inhibitor design","volume":"102","author":"Lecaille","year":"2002","journal-title":"Chem Rev"},{"key":"10.1016\/j.ctrv.2016.02.002_b0515","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.semcancer.2015.08.010","article-title":"Complexity of cancer protease biology: cathepsin K expression and function in cancer progression","volume":"35","author":"Verbov\u0161ek","year":"2015","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.ctrv.2016.02.002_b0520","doi-asserted-by":"crossref","first-page":"452","DOI":"10.3816\/CBC.2010.n.059","article-title":"The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial","volume":"10","author":"Jensen","year":"2010","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.ctrv.2016.02.002_b0525","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/BOR.0b013e32832cbc2a","article-title":"Future therapeutic targets in osteoporosis","volume":"21","author":"Deal","year":"2009","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.ctrv.2016.02.002_b0530","doi-asserted-by":"crossref","first-page":"11393","DOI":"10.1073\/pnas.172398299","article-title":"VEGF-trap: a VEGF blocker with potent antitumor effects","volume":"99","author":"Holash","year":"2002","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.ctrv.2016.02.002_b0535","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S1470-2045(13)70184-0","article-title":"Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial","volume":"14","author":"Tannock","year":"2013","journal-title":"Lancet Oncol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737216000177?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737216000177?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T15:20:40Z","timestamp":1567610440000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737216000177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":107,"alternative-id":["S0305737216000177"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2016.02.002","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2016.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}